Clinical trials: insulin glargine
Diabetes Mellitus, Type 2
RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan
The purpose of the study is to collect information on how Ryzodeg® works in real world participants. Participants will get Ryzodeg® as prescribed to them by the study doctor. The study will last for about 6 to 8 months.
- Trial name
- RESILIENT (NCT03745157)
- Testing
- Insulin Degludec/Insulin Aspart
- Where
- 29 sites in Japan
- Volunteers
- 246 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT00961324
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
Type 2 diabetes mellitus is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily…
- Trial name
- PREVAIL (NCT02194595)
- Testing
- Basal insulin and exenatide, Basal insulin only, Basal insulin and bolus insulin
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Mount Sinai Hospital, Canada
Diabetes Mellitus, Type 1
Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 1 diabetes.
- Trial name
- NCT00127634
- Testing
- Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine
- Where
- 61 sites in United States, Belgium and 4 more
- Volunteers
- 385 people
- Sponsor
- Eli Lilly and Company
Lymphoma, Diabetes Mellitus, Type 2
Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients
There are no guidelines for the management of glucocorticoid- (henceforth steroid) induced elevated blood sugars (henceforth hyperglycemia).
- Conditions
- Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
- Trial name
- NCT02012465
- Testing
- Insulin protocol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Type 1 Diabetes Mellitus
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
Primary Objective: To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c).
- Trial name
- NCT03260868
- Testing
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Where
- 6 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
- Trial name
- BESTMED (NCT05161429)
- Testing
- DPP4, GLP-1 receptor agonist, Basal Insulin
- Where
- 5 sites in United States
- Volunteers
- 550,000 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Primary Objective: To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 Diabetes.
- Trial name
- LIXILAN JP-O2 (NCT02752828)
- Testing
- Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Oral anti-diabetic drugs
- Where
- 113 sites in Japan
- Volunteers
- 521 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look…
- Trial name
- NCT05013229
- Testing
- IcoSema, Insulin glargine, insulin aspart
- Where
- 182 sites in United States, Czechia and 12 more
- Volunteers
- 679 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood…
- Trial name
- NCT00097084
- Testing
- insulin detemir, insulin glargine, insulin aspart
- Where
- 60 sites in United States, Finland and 3 more
- Volunteers
- 324 people
- Sponsor
- Novo Nordisk A/S
Cystic Fibrosis Related Diabetes
Insulin Glargine Vs Standard Insulin Therapy
This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
- Trial name
- NCT00222521
- Testing
- Glargine insulin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 2
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
Primary Objective: To demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients reaching HbA1c (glycosylated hemoglobin) below…
- Trial name
- GALAPAGOS (NCT01121835)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE, PREMIXED INSULIN
- Where
- 96 sites in Austria, Brazil and 14 more
- Volunteers
- 934 people
- Sponsor
- Sanofi
Type 2 Diabetes
Glargine U300 Hospital Trial
The purpose of this study is to find out if treatment with Glargine U300 when compared to Glargine U100 will result in similar sugar control in patients with Type 2 Diabetes (T2D), who are admitted to the hospital and then…
- Trial name
- NCT03013985
- Testing
- Glargine U300, Glargine U100, Glulisine Insulin
- Where
- 4 sites in United States
- Volunteers
- 247 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
Primary Objective: To assess patient preference for Lantus SoloSTAR pen versus Lantus vial and syringe at the end of Crossover Phase (Week 4) in patients with type 2 diabetes mellitus (T2DM) Secondary Objectives: To compare…
- Trial name
- Pen Preference (NCT01226043)
- Testing
- Insulin Glargine
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- Sanofi
Type 2 Diabetes
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Primary Objective: To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c) change from baseline to…
- Trial name
- LixiLan-O (NCT02058147)
- Testing
- Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010)
- Where
- 273 sites in United States, Australia and 21 more
- Volunteers
- 1,170 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes
The purpose of this study is to evaluate whether exenatide is superior to insulin glargine (after 24 weeks) in reducing liver fat content (by MRS) in patients with newly diagnosed type 2 diabetes mellitus and concomitant…
- Trial name
- NCT02303730
- Testing
- Exenatide, insulin glargine
- Where
- 5 sites in China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Diabetes Mellitus, Type 2
A Study for Patients With Type 2 Diabetes
Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.
- Trial name
- NCT01027871
- Testing
- LY2605541, insulin glargine
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 289 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes
Patients with type 1 diabetes trained in multiple daily insulin injection were treated with two diffferent kinds of long acting insulin preparations. The two insulin preparations were glargine and ultralente insulin.
- Trial name
- NCT00276393
- Testing
- Basal insulin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Diabetic Patients With Gastrointestinal Cancer Undergoing Surgery and Receiving Parenteral Nutrition
Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)
Hyperglycemia increases the risk of complications in surgical patients. Focus on poor glycemic control as a contributor to adverse outcomes in settings outside the intensive care unit (ICU) is often dismissed.
- Trial name
- GLUCOSE-in-PN (NCT02216799)
- Testing
- Glargine Insulin, Regular insulin
- Where
- Saudi Arabia
- Volunteers
- 61 people
- Sponsor
- King Faisal Specialist Hospital & Research Center